Alexion Completes Enrollment In AEGIS Study To Evaluate Soliris In Japanese Patients With Genetic Blood Disorder - Quick Facts

Thu. March 20, 2008; Posted: 06:45 AM

(RTTNews) - Alexion Pharmaceuticals Inc. (ALXN | news | PowerRating | PR Charts ) announced the completion of enrolling patients in AEGIS study, a single registration study to evaluate Soliris as a treatment for patients with paroxysmal nocturnal hemoglobinuria, an acquired genetic blood disorder defined by hemolysis.

The company said it over-enrolled total of 29 patients, who will be treated with Soliris at clinical sites throughout Japan for 12 weeks. The company said it targeted enrollment of 25 patients.

The company said it has set the primary efficacy endpoint of the study as reduction of hemolysis from baseline.

For full details on Alexion Pharmaceuticals (ALXN) click here. Alexion Pharmaceuticals (ALXN) has Short Term PowerRatings of 6. Details on Alexion Pharmaceuticals (ALXN) Short Term PowerRatings is available at This Link.

More News: Market Updates | Stock Alerts | All Trading News | Stock Index

Archives

Feedback

Email Article Link

Close X

RELATED SITES

Please call 1-213-955-5858 ext. 1

All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.